Abemaciclib With Endocrine Therapy Receives Expanded Approval for Early Breast Cancer
Lyn Brook
FDA Updates
The FDA has granted approval to abemaciclib (Verzenio®, Eli Lilly and Company) with endocrine therapy—tamoxifen or an aromatase inhibitor—for treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative, node-positive early breast cancer that is at a high risk of recurrence. Patients cons...
Sacituzumab Govitecan-hziy Approved for HR-Positive Breast Cancer
Lyn Brook
FDA Updates
The FDA has granted approval to sacituzumab govitecan-hziy (Trodelvy®, Gilead Sciences, Inc.) for treatment of unresectable, locally advanced, or metastatic hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. Patients are required to have received at least one prior line of endocrine therapy and t...
Elacestrant Approved for ER-Positive, HER2-Negative, ESR1-Mutated Breast Cancer
Lyn Brook
FDA Updates
The FDA has approved elacestrant (Orserdu™, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative, estrogen receptor 1 (ESR1)–mutated advanced or metastatic breast cancer with disease progression subsequent to at least one line of endocrine t...
Addressing Knowledge Gaps in Metastatic Triple-Negative Breast Cancer Treatment and Care
Keira Smith
Breast Cancer Data Hub News
An educational activity provided by i3 Health has delivered significant improvement in knowledge regarding treatment advances and personalized care for patients with metastatic triple-negative breast cancer (TNBC). Breast cancer is the most commonly diagnosed cancer and the second-leading cause of cancer-related death among women in the United Stat...
Uncovering Racial Disparities Experienced in Breast Cancer Patients With Yara Abdou, MD
Lyn Brook
Expert Analysis
At the recent San Antonio Breast Cancer Symposium (SABCS), Yara Abdou, MD, Assistant Professor of Hematology and Oncology and Medical Oncologist at The University of North Carolina School of Medicine, presented her team's research on the disparities that Black women with breast cancer experience. Afterwards, she spoke with Oncology Data Advisor to ...
Highlights from the San Antonio Breast Cancer Symposium With Jason Mouabbi, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Highlights from the San Antonio Breast Cancer Symposium At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Devel...
Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ With Jason Mouabbi, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be prese...
Highlights from the San Antonio Breast Cancer Symposium With Jason Mouabbi, MD
Lyn Brook
Expert Analysis
At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Development of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, shares...
Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ With Jason Mouabbi, MD
Keira Smith
Expert Analysis
In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be presented as a poster at the 2022 San Antonio Breast Cancer Symposium (SABCS).  
The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can foc...
An Introduction to Breast Cancer Therapies: A Patient Resource From Samuel Kareff, MD, MPH
Keira Smith
Expert Analysis
Oncology Data Advisor™ · An Introduction to Breast Cancer Therapies: A Patient Resource From Samuel Kareff, MD, MPH In this interview with Oncology Data Advisor, Dr. Samuel Kareff, a Hematology-Oncology Fellow at Sylvester Comprehensive Cancer Center of the University of Miami, provides a comprehensive overview of the current and emerging therapies used in the treatment of breast cancer, serving as a valuable resource to share with patients who may be discussing these options with their oncology team.  
The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker: Part 2
Keira Smith
Expert Analysis
In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital, launched these retreats at her own institution. In this interview with Oncology Data Advisor, Ms. Shockney and Ms. Metsker reflect on the impactful moments that take place during the retreats and their profound significance for the patients who attend.  Watch the first part of Ms. Shockney and Ms. Metsker's conversation here!
The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker: Part 1
Keira Smith
Expert Analysis
In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital, launched these retreats at her own institution. In this interview with Oncology Data Advisor, Ms. Shockney and Ms. Metsker reflect on the impactful moments that take place during the retreats and their profound significance for the patients who attend.  
Men Can Get Breast Cancer Too: Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Men Can Get Breast Cancer Too: Valerie Brutus, MD, FACS In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor to raise awareness about the reality that men can get breast cancer too. Dr. Brutus explains the risk factors and the conversations that men can have with their health care providers to understand their individual risks for breast cancer. 
Bringing Attention to Breast Cancer Reconstructive Surgery Options With Elizabeth Stirling Craig, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Bringing Attention to Breast Cancer Reconstructive Surgery Options With Elizabeth Stirling Craig, MD In this latest Breast Cancer Awareness Month interview, Dr. Elizabeth Stirling Craig, Director of Microvascular Breast Reconstruction at St. Vincent's Medical Center of Hartford HealthCare, explains the microsurgical techniques that she performs as a breast reconstructive surgeon and shares the importance of providing patients with a clear picture of the reconstructive options that are available to them. 
A Faculty Preview of ODACon™ 2022 Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies
Keira Smith
Expert Analysis
Recently, Oncology Data Advisor hosted a live faculty panel discussion in advance of ODACon™ 2022 Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies, featuring the conference's four expert nurse speakers: Dr. Constance Visovsky, Abbey Kaler, Julia LaBarbera, and Janie Metsker. In their conversation, they gave a preview of ...
An Introduction to Breast Cancer Therapies: A Patient Resource From Samuel Kareff, MD, MPH
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Dr. Samuel Kareff, a Hematology-Oncology Fellow at Sylvester Comprehensive Cancer Center of the University of Miami, provides a comprehensive overview of the current and emerging therapies used in the treatment of breast cancer, serving as a valuable resource to share with patients who may be discussing these options with their oncology team.  
Breast Cancer Is Not Just One Disease: Exploring Lobular Breast Cancer Research With Jason Mouabbi, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Breast Cancer Is Not Just One Disease: Lobular Breast Cancer Research With Jason Mouabbi, MD Understanding the various subtypes of breast cancer is critical, as treatment selection and potential outcomes depend heavily on subtype. In this latest Oncology Data Advisor interview for Breast Cancer Awareness Month, Dr. Jason Mouabbi, an Assistant Professor at the University of Texas MD Anderson Cancer Center, sheds light on lobular breast, an often-understudied subtype. Dr. Mouabbi shares his passion for raising awareness about lobular breast cancer and his goal of better understanding it at the genomic level to develop novel therapeutic options.   
Raising Awareness for Breast Cancer Risks in Transgender Patients With Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor about the risks for breast cancer in transgender individuals. Dr. Brutus shares the importance of starting the conversation about individualized risk assessment to provide the most appropriate screening recommendations and personalized care for every patient.  
Men Can Get Breast Cancer Too: Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor to raise awareness about the reality that men can get breast cancer too. Dr. Brutus explains the risk factors and the conversations that men can have with their health care providers to understand their individual risks for breast cancer. 

Copyright © Oncology Data Advisor. All rights reserved.